Data and Safety Monitoring of COVID-19 Vaccine Clinical Trials
- 19 May 2021
- journal article
- review article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 224 (12) , 1995-2000
Abstract
To speed the development of vaccines against SARS-CoV-2, the United States Federal Government has funded multiple phase 3 trials of candidate vaccines. A single 11-member data and safety monitoring board (DSMB) monitors all government-funded trials to ensure coordinated oversight, promote harmonized designs, and allow shared insights related to safety across trials. DSMB reviews encompass 3 domains: (1) the conduct of trials, including overall and subgroup accrual and data quality and completeness; (2) safety, including individual events of concern and comparisons by randomized group; and (3) interim analyses of efficacy when event-driven milestones are met. Challenges have included the scale and pace of the trials, the frequency of safety events related to the combined enrollment of over 100 000 participants, many of whom are older adults or have comorbid conditions that place them at independent risk of serious health events, and the politicized environment in which the trials have taken place.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
This publication has 10 references indexed in Scilit:
- Developing Safe and Effective Covid Vaccines — Operation Warp Speed’s Strategy and ApproachNew England Journal of Medicine, 2020
- We’re on our ownScience Translational Medicine, 2020
- A perspective on potential antibody-dependent enhancement of SARS-CoV-2Nature, 2020
- A strategic approach to COVID-19 vaccine R&DScience, 2020
- Rapid COVID-19 vaccine developmentScience, 2020
- A review of Dengvaxia®: development to deploymentHuman Vaccines & Immunotherapeutics, 2019
- Protective and immunological behavior of chimeric yellow fever dengue vaccineVaccine, 2016
- The Data and Safety Monitoring Board and Acquired immune deficiency syndrome (AIDS) clinical trialsControlled Clinical Trials, 1995
- RESPIRATORY SYNCYTIAL VIRUS DISEASE IN INFANTS DESPITE PRIOR ADMINISTRATION OF ANTIGENIC INACTIVATED VACCINE12American Journal of Epidemiology, 1969
- RESPIRATORY VIRUS IMMUNIZATIONAmerican Journal of Epidemiology, 1969